Introduction
============

Osteonecrosis or avascular necrosis (AVN) is defined as a pathologic process that results from a critical reduction of blood supply to the bone and elevated intraosseous pressure. Although the pathogenic process is poorly understood, osteonecrosis is the final common pathway of traumatic and non-traumatic insults and compromises the already precarious circulation of the femoral head. Femoral head ischemia subsequently leads to the death of bone marrow and osteocytes and usually results in the collapse of the necrotic segment \[[@B1]\]. AVN is a debilitating disease that usually leads to osteoarthritis of the hip joint in young adults. The disease prevalence is unknown, but estimates indicate that 10,000 to 20,000 new cases are diagnosed in the US each year. Furthermore, it is estimated that 5% to 18% of the more than 500,000 total hip arthroplasties performed annually are related to advanced AVN \[[@B2]\]. Joint-preserving techniques such as core decompression, avascular or vascularized bone grafting, and various femoral osteotomies are most promising in early stages of AVN - Association Research Circulation Osseous (ARCO) stage I and II - with preserved structural integrity of the subchondral plate \[[@B2]\]. The structural collapse of the osteonecrotic segment (ARCO stage III and IV) indicates the progressive course of the disease, and total hip replacement is inevitable in most cases in the long term \[[@B1],[@B3]\].

Cell-based strategies
=====================

To enhance osseous regeneration, the application of osteogenic or angiogenic precursor cells (or both) in combination with or without supporting growth factors is an appealing possibility. Among the various cell types, adult tissue-derived, multipotent mesenchymal stem cells (MSCs) represent a highly promising candidate for cell-based therapeutic approaches \[[@B4]\]. These somatic adult stem cells can be detected in specific tissue compartments of the human body and are considered to play a critical role in maintaining the integrity of different tissues such as skin, bone, and blood \[[@B5]\]. MSCs maintain the ability of mitotic multiplication without significant loss of their specific biomolecular characteristics over extensive population expansion and are capable of differentiating into multiple mesenchymal phenotypes, including osteoblasts, chondrocytes, and adipocytes \[[@B5]\]. MSCs have been shown to enhance tissue regeneration after transplantation in an experimental AVN model in dogs \[[@B6]\]. However, whether the observed effects resulted from the osteogenic differentiation of transplanted cells or are mediated via their trophic activities remains unclear \[[@B6],[@B7]\].

Proper vascularization is essential for the viability and function of the majority of tissues in the body. Without sufficient blood supply, cells suffer from hypoxia, lack of nutrients, and the accumulation of waste products, and biochemical signaling mechanisms are disrupted, affecting tissue homeostasis and preventing tissue regeneration. Endothelial progenitor cells (EPCs) are spindle-shaped cells capable of differentiation into a mature endothelial phenotype. These cells can be isolated from bone marrow and peripheral blood \[[@B8],[@B9]\]. Their role in angiogenesis and neovascularization has been studied extensively, and positive effects on blood vessel formation after transplantation have been reported \[[@B10]\]. So far, however, these cells have not been applied clinically for the treatment of AVN.

Interestingly, Feng and colleagues \[[@B9]\] recently reported significantly decreased numbers of circulating EPCs and colonyforming units (CFUs) in patients with diagnosed AVN in comparison with a healthy control group. Furthermore, EPCs of patients with AVN exhibited impaired migratory capacities and increased cellular senescence, resulting in reduced angiogenesis *in vitro*\[[@B9]\].

Application of concentrated bone marrow aspirates
-------------------------------------------------

Hernigou and colleagues \[[@B11]-[@B13]\] pioneered the clinical application of a cell-based strategy for the treatment of AVN, percutaneously injecting an autologous bone marrow concentrate into the necrotic area of femoral heads. The strategy is driven by the hypothesis that injected bone marrow cells can repopulate the trabecular bone structure and subsequently revitalize and remodel the necrotic bone. For this technique, a bone marrow aspirate is harvested from the iliac crest and the mononuclear cell fraction is isolated. After core decompression, the cell suspension is injected into the necrotic area \[[@B11]-[@B13]\]. These authors reported on the postoperative outcome in 189 cases (116 patients) treated with the injection of autologous bone marrow concentrate \[[@B11]\]. Over the course of the 5- to 10-year follow-up, nine out of 145 patients with early-stage AVN (Steinberg stage I or II) and 25 out of 45 patients with later-stage AVN (Steinberg stage III or IV) required total hip replacement. However, since no control group was examined, the beneficial effect of the injected bone marrow concentrate (that is, in comparison with sole core decompression) is difficult to prove. Gangji and Hauzeur \[[@B14]\] conducted a controlled prospective study comparing the postoperative outcome of core decompression with core decompression followed by the injection of a bone marrow concentrate in early-stage AVN (ARCO stage I or II). The mean follow-up was 2 years, and five out of eight hip joints in the control group showed radiographic progression. In contrast, only one out of 10 hips treated with bone marrow cells progressed to a more severe stage with collapse of the subchondral bone \[[@B14]\]. Recently, Gangji and colleagues \[[@B15]\] reported on the 5-year follow-up of 19 patients (24 hip joints) who received either core decompression alone or core decompression with the additional application of bone marrow concentrate because of early-stage AVN. In this prospective, double-blinded trial, eight out of 11 hip joints in the core decompression group and only three out of 13 joints in the bone marrow concentrate group revealed a disease progression with structural disintegration of the sub-chondral bone \[[@B15]\]. Despite the promising results, the clinical value of these studies is limited because of short-term follow-up periods and low case numbers.

Application of *ex vivo*expanded autologous bone marrow-derived stem cells
--------------------------------------------------------------------------

The *ex vivo*amplification and further administration of MSCs, in contrast to bone marrow cell concentrates, are controlled by regulatory authorities, namely the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) \[[@B16]\]. In most cases, the selection of MSCs is achieved by cell adherence to tissue culture plastic after phase gradient separation (that is, Ficoll or Percoll).

The therapeutic potential of *ex vivo*amplified bone marrow-derived MSCs for the treatment of cortico-steroid-induced AVN in femoral condyles was investigated by Müller and colleagues \[[@B17]\]. In five patients, bone marrow aspirates were harvested from the posterior iliac crest and MSCs were isolated and expanded for three passages. The MSCs were resuspended in 0.1% serum albumin-supplemented saline and transplanted into the necrotic area. After a mean follow-up of 16 months, none of the patients showed signs of disease progression. Owing to the lack of a control group, whether this effect can be attributed to the injected cells is unclear.

Apart from cell delivery in suspension, a variety of matrices, such as ceramics, collagen sponges, hydrogels, and biodegradable polymers, have been used for cell delivery \[[@B4]\]. Core decompression offers the opportunity to deliver such cell-laden biomaterials to the necrotic area. Concurrently with tissue neoformation, scaffolds ideally undergo degradation processes resulting in biocompatible, metabolisable, and excretable by-products. Specifically, for the treatment of AVN, autologous or allogenic bone grafts (demineralized bone matrix, or DBM) as well as synthetic biomaterials (that is, beta-tricalcium phosphate, or β-TCP) have been suggested as suitable carriers for cell-based strategies \[[@B3],[@B4]\].

Kawate and colleagues \[[@B18]\] reported the treatment of three patients with advanced stages of cortisone-induced AVN (Steinberg stage III or IV) with a vascularized fibular graft combined with a synthetic β-TCP ceramic and bone marrow-derived MSCs. Four weeks prior to elective core decompression, 15 mL of bone marrow aspirate was taken from the iliac crest. MSCs were isolated and expanded in autologous serum. After 10 days, MSCs were seeded onto the β-TCP granula and cultured for 2 weeks. After core decompression, the defect was filled with the MSC-seeded β-TCP granula and a vascularized fibular graft was transplanted. During the 34-month follow-up, no progression of the AVN was reported \[[@B18]\]. Given the advanced stages treated and the cortisone-related genesis of the necrosis (both of which have been shown to lead to a decreased therapeutic response in general \[[@B3],[@B19]\]), these results are promising. However, only a small number of patients were treated and a control group was not included.

A similar approach to treat AVN with autologous stromal cell-seeded β-TCP granula was presented by our group \[[@B20]\]. The applied cells consisted of a mixture of MSCs and endothelial and hematopoietic progenitor cells (Tissue Repair Cells, or TRC; Aastrom Biosciences, Inc., Ann Arbor, MI, USA).

Briefly, bone marrow aspirates (100 mL) were harvested bilaterally from the posterior iliac crest. The aspirates were expanded for 12 days in autologous serum-supplemented medium by means of a good manufacturing practice (GMP) system (Aastrom Biosciences, Inc.). Fluorescence-activated cell sorting analysis of the expanded cells showed a significantly higher number of CFU-fibroblasts and cells expressing surface markers characteristic of MSCs (that is, CD90) and hematopoietic (that is, CD133) and endothelial (that is, CD90) progenitor cells when compared with the mononuclear fraction of native bone marrow aspirates, indicating an enrichment of these cell types \[[@B20]\]. Early AVN (ARCO stage II) was diagnosed in all treated patients. After surgical exposure of the proximal femur, a bone plug was removed by using a hollow diamond drill. For the treatment of small AVN lesions (ARCO stage IIA), a K-wire was placed centrally into the necrotic area and was used as a guide for a cannulated 10-mm drill bit. For the treatment of more extensive AVN (ARCO stage IIB and IIC), two drill holes were used (Figure [1A-D](#F1){ref-type="fig"}) \[[@B20]\]. Subsequently, β-TCP granula (Vitoss; Orthovita Inc., Malvern, PA, USA) were placed in a custom-made plastic tray and the TRC suspension was homogeneously seeded onto the granula (Figure [2A](#F2){ref-type="fig"}). For ease of handling, autologous plasma obtained during surgery was used to achieve physical bonding between the MSC-seeded β-TCP granula (Figure [2B](#F2){ref-type="fig"}). The tissue-engineered construct consisting of cells, β-TCP granula, and autologous plasma was administered to the necrotic area through a plastic funnel (Orthovita Inc.) (Figure [2C,D](#F2){ref-type="fig"}), and the drill hole was sealed with the preserved bony cylinder.

![**Intraoperative fluoroscopy demonstrating the drilling prior to stem cell tricalcium phosphate matrix application**. **(A)**A 3-mm K-wire is placed in the anterior portion of the necrosis and **(B)**overdrilled with a 10-mm cannulated drill. **(C,D)**The same procedure is repeated for the posterior part of the necrosis. Reprinted with permission from Schattauer \[[@B54]\].](scrt98-1){#F1}

![**Preparation and application of the stem cell tricalcium phosphate (TCP) matrix**. **(A)**The stem cell suspension is applied to the β-TCP granula. **(B)**This is followed by the addition of intraoperatively obtained autologous serum. **(C,D)**The matrix is transplanted without compression by using a push rod and a custom-made funnel-shaped applicator. Reprinted with permission from Schattauer \[[@B54]\].](scrt98-2){#F2}

At present, a total of four patients have been treated by using the described technique without disease progression (Figure [3A-D](#F3){ref-type="fig"}) at the 24-month follow-up. A European Union-funded (FP-7) clinical phase I and II study is in preparation to evaluate the beneficial effects of bone marrow-derived progenitor cell application compared with standard core decompression in the treatment of early-stage AVN \[[@B21]\].

![**Postoperative radiographs of a 38-year-old patient with avascular necrosis (ARCO stage II) of the right hip**. **(A)**Postoperative x-ray. X-rays of the right hip joint at 6 months **(B)**, 12 months **(C)**, and 24 months **(D)**after treatment. Over time, the sclerotic and necrotic zones have decreased in size, especially on the lateral side. Despite the extensive defect, the femoral head has neither collapsed nor progressed to an ARCO stage III. After 24 months, the beta-tricalcium phosphate (β-TCP) granula have not undergone complete resorption. Reprinted with permission from Schattauer \[[@B54]\]. ARCO, Association Research Circulation Osseous.](scrt98-3){#F3}

Application of allogenic bone marrow-derived stem cells
-------------------------------------------------------

The use of allogenic instead of autologous MSCs for the treatment of AVN appears attractive because of logistic and economic advantages given that these cells might be available as an \'off the shelf\' product. However, allogenic MSCs harbor the danger of disease transmission and immunological rejection \[[@B22]\], as observed in organ transplantation. Therefore, a peculiar risk-benefit analysis of allogenic MSC-based strategies in large populations of patients has to be addressed, especially when aiming for non-life-threatening diseases such as AVN. Because alternative treatment options are lacking, allogenic MSC transplantation appears to be more suitable in severe disorders such as osteogenesis imperfecta. Cell engraftment and accelerated growth velocity have been shown in children with severe osteogenesis imperfecta after systemic administration of isolated allogenic bone marrow-derived MSCs \[[@B23],[@B24]\].

Growth factor-based strategies
==============================

A variety of growth factors produced by osteogenic cells, platelets, and inflammatory cells - including bone morphogenetic proteins (BMPs) \[[@B25]-[@B27]\], insulin-like growth factor-1 and -2, transforming growth factor-β1 (TGF-β1), platelet-derived growth factor, and fibroblast growth factor-2 - are functionally involved in bone healing. The bone matrix serves as a reservoir for these growth factors, which are activated during matrix resorption by matrix metalloproteases. Additionally, the acidic environment that develops during the inflammatory process leads to activation of latent growth factors, which assist in chemo-attraction, migration, proliferation, and differentiation of MSCs into osteoblasts or chondroblasts \[[@B25]-[@B27]\]. All of these functions are driven by complex interactions among growth factors and other cytokines and are influenced by multiple regulatory factors. Thus, the use of osteogenic growth or differentiation factors for joint-preserving treatment of AVN is also a potentially promising approach \[[@B28]\].

Osteogenic growth factors
-------------------------

### Bone morphogenetic proteins

Healing of osseous tissue is regulated mainly by members of the TGF-β superfamily. Specifically, BMPs act to induce the formation of both bone and cartilage by stimulating mesenchymal progenitor cells. However, only a subset of BMPs, notably BMP-2, -4, -7, and -9, have been shown to exhibit osteoinductive activity in *de novo*bone formation \[[@B25]-[@B28]\]. Lieberman and colleagues \[[@B29]\] treated 15 patients (17 hip joints at Ficat stage II or III) after core decompression with allogenic, antigen-extracted, autolyzed fibula grafts, combined with 50 mg of recombinant human BMP-2 and non-collagenous protein. During the mean follow-up of 53 months, three patients (one Ficat stage II and two Ficat stage III) required total hip replacement because of an aggravation of clinical symptoms corresponding with radiographic progression \[[@B29]\].

Mont and colleagues \[[@B30]\] augmented bony defects resulting from AVN with a triphasic bone substitute consisting of DBM, processed allograft bone chips, and a thermoplastic carrier plus the addition of BMP-7 in 19 patients (21 hip joints). Eighty-six percent of the treated hips were assessed as positive outcomes - Harris Hip Score (HHS) of at least 80 - at the final follow-up (mean follow-up of 48 months) \[[@B30]\]. The same group conducted a retrospective cohort study in 33 patients (39 hip joints: 22 at Ficat stage II and 17 at Ficat stage III) implanted with autologous, non-vascularized bone grafts loaded with BMP-7. At the final follow-up (mean of 36 months), only four out of 22 Ficat stage II hips and 11 out of 17 Ficat stage III hips had undergone hip arthroplasty. At present, whether the administration of BMPs results in better clinical outcomes remains unclear as the literature lacks controlled randomized studies that include appropriate numbers of patients and control groups \[[@B31]\].

In another study, Mont and colleagues \[[@B32]\] created an experimental bony defect at the antero- lateral aspect of the femoral head in canines. The defect was augmented with an autologous bone graft from the iliac crest in combination with 250 mg of BMP-7 per gram of autograft. In the control group, the defect remained untreated. Four months after surgery, all control animals showed a collapse of the femoral head with degeneration of the hyaline cartilage. Autograft augmentation with or without BMP-7 preserved the subchondral bone and the production of a surface layer of hyaline cartilage. Independently of BMP supplementation, radiographs revealed good to excellent osseous remodeling when autograft augmentation was performed \[[@B32]\].

The healing potential of BMP-2- and BMP-14-loaded collagen scaffolds was investigated by Simank and colleagues \[[@B33]\] in a sheep model. Necrosis of the femoral head was created by direct ethanol injection. After core decompression, BMP-laden scaffolds were transplanted and compared with non-loaded scaffolds. Three months after surgery, both growth factor-treated groups revealed better bone regeneration histomorphologically \[[@B33]\]. When the same animal model was used, BMP-14-loaded, hydroxyapatite-coated collagen scaffolds (Healos; DePuy, Warsaw, IN, USA) significantly improved bony remodeling of the necrotic area. In comparison, when the scaffold was applied without BMP-14, only partial defect filling with mainly fibrous tissue and persistence of the necrosis was seen after 12 weeks \[[@B34]\].

To achieve long-term availability of osteoinductive or angiogenic growth factors in a defect, it is also possible to deliver gene-modified cells synthesizing and secreting the desired protein. Genetic engineering strategies focusing on osteoinductive factors have emerged as efficient approaches to enhance bone formation. Two modalities are generally used: (a) direct *in vivo*delivery of gene constructs and (b) *ex vivo*transduction and subsequent transplantation of cells expressing the osteoinductive factor \[[@B4]\]. The choice of the gene delivery method depends on several factors, including the particular gene of interest, indication targeted, desired duration of gene expression, and nature of the delivery vector.

Tang and colleagues \[[@B35]\] induced bilateral AVN in goats by ligation of the lateral and medial circumflexing arteries and additional delivery of liquid nitrogen to the femoral head. The authors investigated the influence of MSCs, transduced with either BMP-2 or β-galactosidase and seeded onto β-TCP scaffolds on AVN consolidation. Three weeks after core decompression, the tissue-engineered constructs were transplanted. Whereas control animals (core decompression only) showed AVN progression with structural disintegration and collapse of the subchondral bone 4 months after treatment, no signs of such progression were observed in the cell-treated groups \[[@B35]\]. In the case of BMP-2 transduction, superior bone regeneration in the defects was observed when compared with the β-galactosidase group, as were significantly higher amounts of new bone and higher maximum compressive strength and bone density \[[@B35]\].

Angiogenic growth factors
-------------------------

### Vascular endothelial growth factor

Vascular endothelial growth factor (VEGF) regulates numerous cellular events associated with angiogenesis and vasculogenesis, such as tissue remodeling, during embryonic development and in adults \[[@B36]\]. Yang and colleagues \[[@B37]\] delivered plasmids encoding VEGF immobilized on a collagen carrier into the necrotic area of the femoral head in rabbits. Significantly higher bone formation was reported 8 weeks after treatment in comparison with control animals that received a collagen carrier without VEGF plasmids. The successful *in vivo*transfection of local cells by the VEGF plasmids and expression of VEGF after surgical delivery, however, were shown up to 2 weeks only \[[@B37]\].

Other growth factors
--------------------

### Granulocyte colony-stimulating factor and stem cell factor

Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein, growth factor, and cytokine with two isoforms, both of which stimulate the proliferation of bone marrow stromal cells and enhance their availability in the circulating blood volume \[[@B38]\]. Stem cell factor (SCF) is a cytokine that plays a critical role in regulating the differentiation of hematopoietic stem cells. After intramuscular application of G-CSF and SCF, Wu and colleagues \[[@B39]\] observed increased blood vessel formation (3.3-fold), a higher blood vessel density (2.6-fold), and increased bone formation in the necrotic area of steroid-induced AVN of rabbits in comparison with a non-treated control group. However, whether direct angiogenic/osteogenic differentiation of the mobilized progenitor cells accounted for the increased vascularization and bone formation or whether an increased trophic activity of these cells activated endogenous progenitor cells at the defect site was unclear \[[@B39]\].

### Hepatocyte growth factor

Hepatocyte growth factor (HGF) is a multifunctional cytokine that regulates cell growth, cell motility, and morphogenesis and exhibits synergistic effects with VEGF \[[@B40]\]. Wen and colleagues \[[@B41]\] used a hormone-induced AVN rabbit model to compare the therapeutic effect of core decompression alone versus the additional augmentation of the necrotic area with HGF-transduced MSCs administered in fibrin glue. *De novo*bone formation with regular trabecular structure and enhanced vascularization of the necrotic bone was observed only in animals treated with HGF-transduced MSCs as shown by magnetic resonance imaging and computed tomography imaging and immunohistochemistry \[[@B41]\].

Anterograde osteochondral reconstruction in advanced stages of avascular necrosis
=================================================================================

With the progression of untreated AVN (ARCO stage III and IV), structural disintegration of the subchondral bone occurs and leads to the collapse of the femoral head. A substantial degeneration of the hyaline cartilage has to be assumed at this stage, and retrograde strategies, such as core decompression and autologous bone grafting, offer only very limited prospects \[[@B42]\]. In most of these cases, total joint replacement remains the only treatment option \[[@B43]\]. The potential of regenerative, joint-preserving techniques, such as osteochondral transplantation (autografts or allografts), bone grafting followed by autologous chondrocyte implantation (ACI), or acellular matrix implantation, has not been exploited sufficiently so far. These techniques include a surgical dislocation of the hip to anterogradely access the osteochondral defect, which is more invasive and surgically demanding \[[@B42],[@B44]\].

Osteochondral transplantation (mosaicplasty)
--------------------------------------------

Meyers and colleagues \[[@B45],[@B46]\] transplanted osteochondral autografts or allografts in 21 patients with progressed stages of AVN (Ficat stage II to IV) after hip dislocation and debridement of the osteochondral defect. The treatment was reported to be successful in 71% to 80% of all cases (follow-up for 1.5 to 5 years) but in only 50% of the patients with steroid-induced AVN \[[@B45],[@B46]\]. Sotereanos and colleagues \[[@B47]\] treated a 36-year-old patient after ineffective core decompression and vascularized fibula graft augmentation. Three osteochondral cylinders were transferred from a non-weight-bearing area at the inferior-lateral femoral head into the defect following bone grafting. After 5 years, the HHS was 96, the patient was pain-free, and the range of motion was not limited \[[@B47]\].

Rittmeister and colleagues \[[@B48]\] performed an autologous osteochondral transfer (one to three grafts) in five patients with advanced AVN. After a mean follow-up of 57 months, the therapy failed in four patients and total hip arthroplasty was required. Only one patient was treated successfully, and hip function showed no limitations 31 months after surgery \[[@B48]\].

Autologous chondrocyte implantation
-----------------------------------

ACI has been proven to be a suitable technology for the treatment of full-thickness cartilage defects in the knee and ankle joint. Its therapeutic potential in the hip has not been addressed sufficiently so far. Only one case report on ACI at the femoral head has been published so far. Akimau and colleagues \[[@B49]\] treated a 31-year-old man with a diagnosed post-traumatic necrosis of the femoral head by using a modified first-generation ACI approach. Healthy hyaline cartilage (240 mg) was harvested arthroscopically from the ipsilateral knee joint, and chondrocytes were isolated and expanded in monolayer culture over a period of 3 weeks. In a second surgery, the femoral head was dislocated and exposed. After removal of the degenerated cartilage and necrotic bone, the defect was covered with a collagen type I membrane (Chondro-Gide; Geistlich, Wolhusen, Switzerland), and 6 × 10^6^chondrocytes were injected underneath the membrane. The HHS increased from 45 preoperatively to 76 at 12 and 18 months after surgery. Arthroscopic biopsy revealed a 2 mm-thick repair tissue consisting of fibrous and, to a lesser extent, hyaline-like cartilage \[[@B49]\].

Acellular matrix implantation
-----------------------------

Matrix-based ACI has been shown to be a clinically successful method for the treatment of full-thickness cartilage defects by using a variety of scaffold materials \[[@B4],[@B50],[@B51]\]. In ACI, a previous cartilage biopsy harvest followed by *ex vivo*cell processing, which is timeconsuming and costly, is required. To circumvent these barriers, an innovative one-step procedure combining microfracturing \[[@B52]\] of the subchondral bone and coverage of the cartilage defect by using an acellular scaffold (Autologous Matrix-Induced Chondrogenesis) was developed \[[@B53]\]. We recently adopted this basic principle for the treatment of an advanced stage of AVN in the hip (ARCO stage III) as shown in Figure [4](#F4){ref-type="fig"}. The hip joint was dislocated after a trochanteric flip osteotomy was performed \[[@B44]\] and the femoral head was exposed (Figure [4](#F4){ref-type="fig"}). The osteochondral defect was debrided, the sclerotic bony ground was repeatedly penetrated by using a small drill bit, and the bony defect was augmented with autologous cancellous bone. Subsequently, the cartilage defect was replenished by using an acellular collagen type I hydrogel (CaReS-OneStep; Arthro Kinetics, Krems, Austria) \[[@B54]\]. So far, three patients have been treated with this technique with a follow-up of 9 months.

![**Acellular matrix implantation in a patient with an osteochondral defect of the femoral head and an unstable cartilage defect (ARCO stage III)**. A trochanteric flip osteotomy \[[@B43]\] was performed to expose the femoral head. **(A)**Intraoperative view after surgical dislocation, debridement, and anterograde drilling into the sclerotic bone. **(B)**Aspect of the defect after bone grafting by using cancellous bone from the osteotomy. **(C)**The cartilaginous portion of the lesion was augmented with an acellular collagen type I hydrogel (CaReS^®^-OneStep; Arthro Kinetics, Krems, Austria). **(D)**Schematic illustration of the procedure. ARCO, Association Research Circulation Osseous.](scrt98-4){#F4}

Conclusions
===========

Core decompression is the gold standard technique for the treatment of early-stage AVN of the femoral head \[[@B55]-[@B57]\] and reveals superior clinical outcome in comparison with non-operative treatment regimens \[[@B58],[@B59]\]. The variable and unpredictable clinical outcome led to the development of complex surgical techniques, such as the transplantation of non-vascularized/vascularized autologous bone grafts, aiming \[[@B31],[@B60]\] for a more reliable bone regeneration and preservation of a physiological joint function. Extensive research activities over the last decade explored the potential of mesenchymal progenitor cells \[[@B4]-[@B7]\] and growth factors \[[@B4],[@B5],[@B25],[@B27],[@B28],[@B35],[@B37],[@B54]\], aiming for an autologous *ex vivo*or *in vivo*regeneration of a variety of musculoskeletal tissues.

Early promising clinical data on the application of concentrated bone marrow cells, isolated bone marrow-derived progenitor cells, and growth factors for the treatment of AVN have been reported \[[@B3],[@B11]-[@B15],[@B31],[@B32]\]. However, so far, both cell- and growth factor-based strategies undertaken lacked randomized clinical trials to sufficiently validate their efficiency in comparison with conventional therapies. Whether and to what extent the observed bone regeneration resulted from the applied cells or growth factors remain uncertain.

In addition, *ex vivo*processed/expanded cells are classified as advanced therapy medicinal products (ATMPs) by the competent international and national regulatory agencies (for example, the FDA and the EMA). ATMPs have to fulfill specific quality and safety criteria that rely on standardized GMP conditions for cell processing, the performance of adequate preclinical animal models for the targeted disease, and controlled clinical phase I/II trials \[[@B16]\]. This increases time- and cost-consuming barriers on the way to FDA/EMA approval on the one hand but provides the opportunity to investigate the potential of cell-based strategies in musculoskeletal diseases guided by a controlled regulatory framework on the other hand. Also, owing to unresolved safety concerns, the clinical translation of gene therapy approaches for the treatment of AVN is currently not feasible at all.

The treatment of osteochondral defects in advanced stages of AVN, characterized by a collapse of the subchondral bone, remains an unresolved burden in orthopedic surgery \[[@B1]-[@B3]\]. As a result, the predominantly young patients usually require total hip arthroplasty \[[@B2],[@B3],[@B61]\]. At present, the applicability of regenerative joint-preserving techniques, such as matrix-based ACI or osteochondral transplantation, has not been adequately addressed. One reason is likely the technically demanding surgical hip dislocation required for anterograde access to the femoral head \[[@B44]\].

Applying tissue engineering-based techniques for joint preservation approaches could have great therapeutic potential in the restoration of femoral head integrity \[[@B4],[@B28],[@B54]\]. It is noteworthy that the few case reports recently published have shown heterogeneous results, ranging from complete therapeutic failure to full recovery with restored hip function \[[@B45]-[@B49]\]. Full evaluation of the promising therapeutic potential of these novel regenerative strategies for AVN will require rigorous randomized controlled trials that address stage-dependent treatment of the disease.
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Additional information
======================

The ARCO, Ficat, and Steinberg classifications rely on radiographic and magnetic resonance imaging to determine the severity of AVN of the femoral head. In general, stage/grade I and II reflect early AVN with an intact subchondral plate, whereas stage/grade III and IV describe more advanced AVN with a collapse of the subchondral plate \[[@B55]\]. The HHS is based on a standardized assessment form to evaluate the clinical function of the hip joint. The HHS is reported as 100 for an excellent hip function and 0 for a very bad hip function.
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